<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076856</url>
  </required_header>
  <id_info>
    <org_study_id>P03247</org_study_id>
    <nct_id>NCT00076856</nct_id>
  </id_info>
  <brief_title>Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)</brief_title>
  <official_title>A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate improvement in overall survival for the
      combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT
      alone. Secondary objective is to demonstrate an improvement in the time to radiological CNS
      progression with the addition of TMZ to WBRT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2004</start_date>
  <completion_date type="Actual">March 31, 2006</completion_date>
  <primary_completion_date type="Actual">March 31, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to radiological CNS progression</measure>
  </secondary_outcome>
  <enrollment type="Actual">95</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Brain Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Age greater than or equal to 18

          -  Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)

          -  At least one brain metastasis diagnosed within 30 days of randomization

          -  Brain metastases must not have been previously treated with WBRT or radiosurgery

          -  No more than 2 sites of extracranial metastases

          -  May have received prior radiation therapy to the primary tumor and/or systemic
             metastatic sites

          -  Meets protocol requirements for specified laboratory values.

          -  Written informed consent and cooperation of patient

          -  Appropriate use of effective contraception if of childbearing potential.

          -  Karnofsky Performance Status KPS greater than 70

          -  Score less than 2 on all criteria of the Comprehensive Neurological Outcome Scale
             (CNOS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Chua D, Krzakowski M, Chouaid C, Pallotta MG, Martinez JI, Gottfried M, Curran W, Throuvalas N. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer. 2010 May;11(3):176-81. doi: 10.3816/CLC.2010.n.022.</citation>
    <PMID>20439193</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2004</study_first_submitted>
  <study_first_submitted_qc>February 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2004</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Links</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

